Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy
- PMID: 21952105
- DOI: 10.1097/IAE.0b013e3182252aa8
Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy
Abstract
Purpose: To study the morphologic features of serous retinal detachment, the photoreceptor inner and outer segment junction line, retinal pigment epithelium irregularities, pigment epithelial detachment, and the subfoveal choroid before and after treatment of chronic central serous chorioretinopathy, using spectral-domain optical coherence tomography.
Methods: We studied 17 eyes of 17 consecutive patients (all men) with chronic central serous chorioretinopathy. We performed photodynamic therapy (PDT) with half-dose (3 mg/m2) verteporfin. We studied morphologic features using spectral-domain optical coherence tomography before and at 1, 3, 6, and 12 months after PDT.
Results: Retinal detachment showed reattachment in 16 of the 17 eyes by 3 months after PDT. The inner and outer segment junction line could be visualized in 13 eyes at 6 months after PDT. Retinal pigment epithelium irregularities were confirmed in all 17 eyes before and during the year after PDT. Pigment epithelial detachment initially disappeared but then recurred in 5 eyes after PDT. Subfoveal highly reflective substances first lessened in intensity but then again became prominent in 2 eyes.
Conclusion: The authors identified recurrent pigment epithelial detachment and/or retinal detachment during the 1-year period after PDT. Even if retinal detachment initially disappears, retinal pigment epithelium or choroidal morphologic changes can still develop. The effect of half-dose PDT for chronic central serous chorioretinopathy may thus be temporary.
Similar articles
-
Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.Am J Ophthalmol. 2012 Sep;154(3):579-85. doi: 10.1016/j.ajo.2012.03.043. Epub 2012 Jul 20. Am J Ophthalmol. 2012. PMID: 22818904
-
Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.Int Ophthalmol. 2017 Jun;37(3):483-489. doi: 10.1007/s10792-016-0286-4. Epub 2016 Jul 8. Int Ophthalmol. 2017. PMID: 27392913
-
Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.Retina. 2011 Apr;31(4):772-8. doi: 10.1097/IAE.0b013e3181f049d3. Retina. 2011. PMID: 20890236
-
[Evaluation of the choroid in central serous chorioretinopathy].Nippon Ganka Gakkai Zasshi. 2012 Nov;116(11):1062-79. Nippon Ganka Gakkai Zasshi. 2012. PMID: 23316655 Review. Japanese.
-
[Pathophysiology of macular diseases--morphology and function].Nippon Ganka Gakkai Zasshi. 2011 Mar;115(3):238-74; discussion 275. Nippon Ganka Gakkai Zasshi. 2011. PMID: 21476310 Review. Japanese.
Cited by
-
Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2063-73. doi: 10.1007/s00417-014-2926-6. Epub 2015 Jan 24. Graefes Arch Clin Exp Ophthalmol. 2015. PMID: 25616728
-
Central serous chorioretinopathy: update on pathophysiology and treatment.Surv Ophthalmol. 2013 Mar-Apr;58(2):103-26. doi: 10.1016/j.survophthal.2012.07.004. Surv Ophthalmol. 2013. PMID: 23410821 Free PMC article. Review.
-
Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1141-1148. doi: 10.1007/s00417-017-3626-9. Epub 2017 Mar 10. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28283732 Clinical Trial.
-
Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.Eur J Med Res. 2012 Jul 12;17(1):22. doi: 10.1186/2047-783X-17-22. Eur J Med Res. 2012. PMID: 22788836 Free PMC article.
-
Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy.Clin Ophthalmol. 2013;7:1867-75. doi: 10.2147/OPTH.S32177. Epub 2013 Sep 19. Clin Ophthalmol. 2013. PMID: 24092965 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical